Abstract
Objective: Neoadjuvant chemotherapy (NACT) followed by surgery is a different therapeutic approach to locally advanced cervical adenocarcinoma (LACA) and seems to offer specific advantages over chemoradiation. This phase II trial was designed to evaluate the toxicity and activity of NACT with cisplatin-adriamycin-paclitaxel (TAP) in patients with LACA. Methods: Patients with International Federation of Gynecology and Obstetrics stage IB2-IIB uterine adenocarcinoma were treated with NACT TAP for 3 cycles. After the last cycle, patients underwent radical surgery with lymph node dissection. Pathological response was classified as no residual tumor (pCR), residual disease with less than 3-mm stromal invasion (pR1), or residual disease with more than 3-mm stromal invasion (pR2). Results: Between 2003 and 2010, 30 women were enrolled. Fourteen complete clinical responses, 10 partial responses, and 6 stabilizations of disease were registered. Three patients achieved a pCR, 6 a pR1 response, and 21 a pR2 response. At a median follow-up of 45 months, progression-free survival and overall survival were 37 and 48 months, respectively. Hematologic toxicity was the most relevant adverse effect. Conclusions: The TAP combination seems to be feasible with an acceptable toxicity profile and a promising response rate for the treatment of LACA.
| Original language | English |
|---|---|
| Pages (from-to) | 729-734 |
| Number of pages | 6 |
| Journal | International Journal of Gynecological Cancer |
| Volume | 24 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Cervical cancer adenocarcinoma
- Neoadjuvant chemotherapy
- Surgery
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Oncology
- Medicine(all)
Cite this
Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma. / Lorusso, Domenica; Ramondino, Stefano; Mancini, Maria; Zanaboni, Flavia; Ditto, Antonino; Raspagliesi, Francesco.
In: International Journal of Gynecological Cancer, Vol. 24, No. 4, 2014, p. 729-734.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial on cisplatin-adriamycin-paclitaxel combination as neoadjuvant chemotherapy for locally advanced cervical adenocarcinoma
AU - Lorusso, Domenica
AU - Ramondino, Stefano
AU - Mancini, Maria
AU - Zanaboni, Flavia
AU - Ditto, Antonino
AU - Raspagliesi, Francesco
PY - 2014
Y1 - 2014
N2 - Objective: Neoadjuvant chemotherapy (NACT) followed by surgery is a different therapeutic approach to locally advanced cervical adenocarcinoma (LACA) and seems to offer specific advantages over chemoradiation. This phase II trial was designed to evaluate the toxicity and activity of NACT with cisplatin-adriamycin-paclitaxel (TAP) in patients with LACA. Methods: Patients with International Federation of Gynecology and Obstetrics stage IB2-IIB uterine adenocarcinoma were treated with NACT TAP for 3 cycles. After the last cycle, patients underwent radical surgery with lymph node dissection. Pathological response was classified as no residual tumor (pCR), residual disease with less than 3-mm stromal invasion (pR1), or residual disease with more than 3-mm stromal invasion (pR2). Results: Between 2003 and 2010, 30 women were enrolled. Fourteen complete clinical responses, 10 partial responses, and 6 stabilizations of disease were registered. Three patients achieved a pCR, 6 a pR1 response, and 21 a pR2 response. At a median follow-up of 45 months, progression-free survival and overall survival were 37 and 48 months, respectively. Hematologic toxicity was the most relevant adverse effect. Conclusions: The TAP combination seems to be feasible with an acceptable toxicity profile and a promising response rate for the treatment of LACA.
AB - Objective: Neoadjuvant chemotherapy (NACT) followed by surgery is a different therapeutic approach to locally advanced cervical adenocarcinoma (LACA) and seems to offer specific advantages over chemoradiation. This phase II trial was designed to evaluate the toxicity and activity of NACT with cisplatin-adriamycin-paclitaxel (TAP) in patients with LACA. Methods: Patients with International Federation of Gynecology and Obstetrics stage IB2-IIB uterine adenocarcinoma were treated with NACT TAP for 3 cycles. After the last cycle, patients underwent radical surgery with lymph node dissection. Pathological response was classified as no residual tumor (pCR), residual disease with less than 3-mm stromal invasion (pR1), or residual disease with more than 3-mm stromal invasion (pR2). Results: Between 2003 and 2010, 30 women were enrolled. Fourteen complete clinical responses, 10 partial responses, and 6 stabilizations of disease were registered. Three patients achieved a pCR, 6 a pR1 response, and 21 a pR2 response. At a median follow-up of 45 months, progression-free survival and overall survival were 37 and 48 months, respectively. Hematologic toxicity was the most relevant adverse effect. Conclusions: The TAP combination seems to be feasible with an acceptable toxicity profile and a promising response rate for the treatment of LACA.
KW - Cervical cancer adenocarcinoma
KW - Neoadjuvant chemotherapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=84900456293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900456293&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000115
DO - 10.1097/IGC.0000000000000115
M3 - Article
VL - 24
SP - 729
EP - 734
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 4
ER -